Iterum Therapeutics Received Notice of Delisting

robot
Abstract generation in progress

Iterum Therapeutics (ITRM) has received a Nasdaq determination to delist its ordinary shares due to noncompliance with the $1.00 bid price rule and the $35 million market value standard. Trading is scheduled to be suspended on March 5, 2026, unless the company requests a hearing. The company also remains out of compliance with related equity and net income requirements.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)